



COLORADO

Department of Health Care
Policy & Financing

**AGENDA: DUR BOARD MEETING
Colorado Medicaid DUR
Department of Health Care Policy and Financing**

Skaggs School of Pharmacy and Pharmaceutical Sciences Building
12850 East Montview Blvd, Aurora CO 80045
Seminar Room- Room 1000; First floor
Parking available in the Henderson/Visitor Parking Garage

August 16, 2016

5:30 p.m. Closed Executive Session for Board Members

6:30 p.m. – 9:00 p.m. Open Session

DUR BOARD MEMBERS and CO DUR MEMBERS

LeWayne Garrison, RPh
Karen Weber, DO
Pam Reiter, PharmD
Sheila Botts, PharmD
Kerstin Froyd, MD
Jim Regan, MD
Laura Borgelt, PharmD
Alex Reish, DO

Robert Lodge, PharmD
Robert L Page, PharmD, MSPH
(CO DUR)
Nila Mahyari, PharmD (CO DUR)
Jon Campbell, PhD (CO DUR)
Gina Moore, PharmD

1. Roll Call

2. Approval of the minutes from the May 24, 2016 meeting

3. Rules

- Agenda items must be approved in advance, including requests to present information. Please contact Robert Lodge at (303) 866-3105 if you want to add an agenda item. Visitors are welcome during the open portion of the meeting only.
- Anyone wishing to provide testimony must contact the DUR Coordinator Robert Lodge (Robert.Lodge@state.co.us) at 303-866-3105 or at least 24 hours before the meeting.



4. Executive Session (Closed)

- Approval of the minutes from the previous meeting
- Review Retro-DUR reports
- Tele-Consult Program Summary Report
- Quarterly Drug Utilization Reports
- FDA updates
- Summary of Most Recent Module

5. Open Session

A. Unfinished Business and General Orders

Update on the following (Update from May DUR meeting. No discussion):

- Antihistamine and combinations
- Angiotensin Receptor Blockers and combinations
- Renin Inhibitor and combinations
- Fibromyalgia agents
- Long-Acting Oral Opioids
- Inhaled Anticholinergics and combinations
- Inhaled Long-Acting Beta Agonists
- Inhaled Corticosteroids and combinations
- Skeletal Muscle Relaxants
- Testosterone Products
- Topical Immunomodulators

B. New Business

Proposed Criteria for current PDL:

- Hepatitis C agents
- Oral anticoagulants
- Bisphosphonates
- Oral biguanides
- Erythropoiesis stimulating agents
- Hypoglycemic combinations
- Meglitinides
- DPP4 inhibitors
- GLP-1 analogues
- SGLT-2 inhibitors
- Amylin agents
- Thiazolidinediones
- Overactive bladder agents
- Stimulants and other ADHD agents



New Topics for Discussion:

- ProDUR Edits Discussion
 - Refill too soon policy update
- New Approved Drug Policy

6. Adjourn

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303- 866-3105 or robert.lodge@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

